TY - JOUR
T1 - Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells
AU - Sheu, Jim Jinn Chyuan
AU - Guan, Bin
AU - Tsai, Fuu Jen
AU - Hsiao, Erin Yi Ting
AU - Chen, Chih Mei
AU - Seruca, Raquel
AU - Wang, Tian Li
AU - Shih, Ie Ming
PY - 2012/3
Y1 - 2012/3
N2 - Although the oncogenic functions of activating BRAF mutations have been clearly demonstrated in human cancer, their roles in nontransformed epithelial cells remain largely unclear. Investigating the cellular response to the expression of mutant BRAF in nontransformed epithelial cells is fundamental to the understanding of the roles of BRAF in cancer pathogenesis. In this study, we used two nontransformed cyst108 and RK3E epithelial cell lines as models in which to compare the phenotypes of cells expressing BRAF WT and BRAF V600E. We found that transfection of the BRAF V600E, but not the BRAF WT, expression vector suppressed cellular proliferation and induced apoptosis in both cell types. BRAF V600E generated reactive oxygen species, induced DNA double-strand breaks, and caused subsequent DNA damage response as evidenced by an increased number of pCHK2 and γH2AX nuclear foci as well as the up-regulation of pCHK2, p53, and p21. Because BRAF and KRAS (alias Ki-ras) mutations have been correlated with GLUT1 up-regulation, which encodes glucose transporter-1, we demonstrated here that expression of BRAF V600E, but not BRAF WT, was sufficient to up-regulate GLUT1. Taken together, our findings provide new insights into mutant BRAF-induced oncogenic stress that is manifested by DNA damage and growth arrest by activating the pCHK2-p53-p21 pathway in nontransformed cells, while it also confers tumor-promoting phenotypes such as the up-regulation of GLUT1 that contributes to enhanced glucose metabolism that characterizes tumor cells.
AB - Although the oncogenic functions of activating BRAF mutations have been clearly demonstrated in human cancer, their roles in nontransformed epithelial cells remain largely unclear. Investigating the cellular response to the expression of mutant BRAF in nontransformed epithelial cells is fundamental to the understanding of the roles of BRAF in cancer pathogenesis. In this study, we used two nontransformed cyst108 and RK3E epithelial cell lines as models in which to compare the phenotypes of cells expressing BRAF WT and BRAF V600E. We found that transfection of the BRAF V600E, but not the BRAF WT, expression vector suppressed cellular proliferation and induced apoptosis in both cell types. BRAF V600E generated reactive oxygen species, induced DNA double-strand breaks, and caused subsequent DNA damage response as evidenced by an increased number of pCHK2 and γH2AX nuclear foci as well as the up-regulation of pCHK2, p53, and p21. Because BRAF and KRAS (alias Ki-ras) mutations have been correlated with GLUT1 up-regulation, which encodes glucose transporter-1, we demonstrated here that expression of BRAF V600E, but not BRAF WT, was sufficient to up-regulate GLUT1. Taken together, our findings provide new insights into mutant BRAF-induced oncogenic stress that is manifested by DNA damage and growth arrest by activating the pCHK2-p53-p21 pathway in nontransformed cells, while it also confers tumor-promoting phenotypes such as the up-regulation of GLUT1 that contributes to enhanced glucose metabolism that characterizes tumor cells.
UR - http://www.scopus.com/inward/record.url?scp=84863152979&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2011.11.026
DO - 10.1016/j.ajpath.2011.11.026
M3 - 文章
C2 - 22227015
AN - SCOPUS:84863152979
SN - 0002-9440
VL - 180
SP - 1179
EP - 1188
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 3
ER -